This observational study evaluates a nutraceutical combination consisting of Tanacetum parthenium, 5-hydroxytryptophan (5-HTP) derived from Griffonia simplicifolia, and magnesium (AuraSTOP®) in the clinical setting of episodic migraine without aura.

Episodic migraine without aura is one of the most common forms of primary headache, characterized by recurrent attacks of moderate-to-severe pain, often accompanied by nausea, photophobia, and phonophobia, with a significant impact on quality of life and productivity.1.

The primary objective of the study was to evaluate the reduction in the frequency of migraine attacks in participants who took the combination therapy for a specified observation period. Secondary endpoints included a reduction in pain intensity, a decrease in the use of symptomatic medications, and an improvement in perceived quality of life.

The biological rationale of the combination is based on the pathophysiological mechanisms of migraine. Tanacetum parthenium (partenium) is known for its anti-inflammatory properties and the ability to modulate the release of mediators involved in neuroinflammation2. 5-HTP, a direct precursor of serotonin, contributes to the regulation of serotonergic systems, altered in migraine patients3. Finally, magnesium plays a role in the stabilization of neuronal membranes and in the modulation of cortical excitability, often being lacking in subjects with migraines.4

The results of the study show a significant reduction in the average number of days with migraines per month in those who took AuraSTOP®. There is also a decrease in the intensity of the attacks and a lower use of analgesic or triptan drugs. The use of AuraSTOP was generally well tolerated, with mild and transitory side effects, confirming the good safety profile of the nutraceutical combination.

The authors conclude that the association of Tanacetum Parthenium, 5-HTP and Magnesium can be a potentially effective and safe option for those suffering from aura-free episodic migraine, especially in those who do not tolerate or do not want to traditional drug therapies. However, since it is an observational and non-randomized study, the need for controlled clinical studies and on larger samples is emphasized to confirm the results and define comparative efficacy with greater precision than standard therapies.

In summary, the study suggests that a nutraceutical approach aimed at the main neurobiological mechanisms of migraine can offer valid support for use at the time of the attack in the case of episodic migraine without aura.

  1. Headache Classification Committee of the International Headache Society. (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia: An International Journal of Headache, 38(1), 1–211.
  2. Wider B., et al. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015;4(4):CD002286.
  3. Aggarwal M., et al. Serotonin and CGRP in migraine. Ann Neurosci. 2012;19(2):88-94.
  4. Sun-Edelstein C., et al. Role of magnesium in the pathogenesis and treatment of migraine. Expert Rev Neurother. 2009;9(3):369-79.

Related articles